The therapeutic potential of psilocybin in anorexia nervosa in young adults
Phase 2 – studying effectiveness and dosage
Conditions:
Anorexia Nervosa
Sponsor: Region Skane
trial.available_in:
БГ
Overview
Trial status: Authorised
General Anxiety (GAD-2), Patient Health Questionnaire (PHQ-2), Experiences in Close Relationships – (ECR–RS), Life Satisfaction (LS), Positive & Neg Affect (PANAS), Harmony in Life (HILS), Self-compassion (Short SCS), Ten Item Pers Inv (TIPI), AN symptom severity (EDE), Response: A clinically significant improvement in weight and psychological symptoms during the treatment period., Remission: The achievement and maintenance of weight restoration and psychological well-being, with no significant symptoms of anorexia nervosa., Relapse: Defined as a composite outcome during the 6-month follow-up period
Incidence of adverse events (AEs) and serious adverse events (SAEs) during the trial period.
Description
General Anxiety (GAD-2), Patient Health Questionnaire (PHQ-2), Experiences in Close Relationships – (ECR–RS), Life Satisfaction (LS), Positive & Neg Affect (PANAS), Harmony in Life (HILS), Self-compassion (Short SCS), Ten Item Pers Inv (TIPI), AN symptom severity (EDE), Response: A clinically significant improvement in weight and psychological symptoms during the treatment period., Remission: The achievement and maintenance of weight restoration and psychological well-being, with no significant symptoms of anorexia nervosa., Relapse: Defined as a composite outcome during the 6-month follow-up period
Who can participate
Age group: 0-17 years, 18-64 years
Gender: Female, Male
Target enrollment: 40 participants
БГ